Tequin

Lea en español

TequinTequin, one of the brand names for the pharmaceutical product Gatifloxacin, was introduced to the U.S. market by Bristol-Myers Squibb in 1999. The drug, an antibiotic, was prescribed primarily for the treatment of respiratory tract infections.

In 2006, a report in the New England Journal of Medicine alleged that Tequin had been found to put users at an elevated risk for dysglycemia, a blood sugar metabolism disorder that may manifest as either hyperglycemia (high blood sugar) or hypoglycemia (low blood sugar). Initially, Bristol-Myers Squibb notified health care providers that product warnings would be enhanced. However, the company subsequently opted to terminate the manufacture of Tequin. The product is now available only as treatment for eye conditions, in the form of an eye drop.

If you experienced side effects after being prescribed Tequin, GetLegal has the tools and resources to help you find skilled legal representation to protect your rights. Visit our attorney directory, look for your geographic location and find the best lawyer for your situation.

Defective Drugs & Medical Devices Topics

Latest Articles

The 25th Amendment to the United States Constitution Is in the News

The Constitutional Process for Replacing a President Who Lacks Capacity to Serve The United States C…

15 Oct 2020, Thursday

The Legal Consequences of Voting Twice

Why You Shouldn’t Follow Trump’s Suggestion to “Test Integrity of Electoral System” | P…

21 Sep 2020, Monday

Medical Malpractice: How It Differs from Other Negligence Claims

The Standard of Care – What You Must Prove to Recover for Your Losses When you’re hurt in an…

21 Aug 2020, Friday